Announcements
- Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
- Collegium to Participate in Jefferies Global Healthcare Conference
- Collegium Announces $35 Million Accelerated Share Repurchase Program
- Collegium Reports First Quarter 2024 Financial Results
- Collegium Announces CEO Transition
- Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
- Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
More ▼
Key statistics
As of last trade Collegium Pharmaceutical Inc (354:FRA) traded at 30.40, -20.00% below its 52-week high of 38.00, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 30.40 |
---|---|
High | 30.40 |
Low | 30.40 |
Bid | 30.40 |
Offer | 30.80 |
Previous close | 29.60 |
Average volume | 7.22 |
---|---|
Shares outstanding | 32.72m |
Free float | 32.23m |
P/E (TTM) | 15.51 |
Market cap | 1.04bn USD |
EPS (TTM) | 2.06 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 07:10 BST.
More ▼